In Study 2, we used a combination protocol of survivin peptide vaccination with IFN alpha in an attempt to enhance the immunogenicity, as with colorectal [13] and pancreatic cancers [14]. The gene discussed is BIRC5; the disease is pancreatic neoplasm.